Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study
单位:[1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University临床科室国家中心消化分中心消化内科首都医科大学附属北京友谊医院[2]Department of Medical Statistics, Peking University First Hospital, Beijing[3]Department of Gastroenterology, Nanfang Hospital of Southern Medical University[4]Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou院本部内科消化内科中山大学附属第一医院[5]Department of Gastroenterology, Changhai Hospital Affiliated to the Second Military Medical University[6]Department of Gastroenterology, Zhongshan Hospital, Fudan University[7]Department of Gastroenterology, Renji Hospital, Shanghai Jiaotong University, Shanghai[8]Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou[9]Department of Gastroenterology, The First Affiliated Hospital of Xi’an Jiaotong University, Xian, China
Objective The topical antispasmodic agent l-menthol is commonly used for gastric peristalsis suppression during diagnostic upper gastrointestinal (GI) endoscopy. We evaluated the efficacy and safety of a single dose l-menthol solution in suppressing gastric peristalsis during upper GI endoscopy in Chinese patients. Methods In this phase III, multicenter, randomized, double-blind, placebo-controlled study (ClinicalTrials.gov: NCT03263910), 220 patients scheduled to undergo upper GI endoscopy at five Chinese referral centers received a single dose of either 160 mg of l-menthol (n = 109) or placebo (n = 111). Both treatments were sprayed endoscopically on the gastric mucosa. An independent committee evaluated the degree of gastric peristalsis (peristaltic score: grade 1-5). Results At baseline, the proportion of patients with grade 1 peristalsis (no peristalsis) did not differ between the groups. The proportion of patients with grade 1 peristalsis post-treatment was significantly higher in the l-menthol group (40.37%, 44/109) versus the placebo group (16.22%, 18/111; P < 0.001); the difference between the groups was 24.15% (95% confidence interval: 12.67%-35.63%; P < 0.001). In the l-menthol group, 61.47% of patients had grade 1 peristalsis after endoscopy versus 24.55% in the placebo group (P < 0.001). The ease of intragastric examination correlated significantly with the grade of peristalsis. The incidence of adverse events was comparable between the groups (P = 0.340). Conclusions During upper GI endoscopy, a single dose of l-menthol solution (160 mg) sprayed on the gastric mucosa significantly attenuated gastric peristalsis versus placebo, thereby improving the visual stability without any safety concerns.
第一作者单位:[1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University
通讯作者:
通讯机构:[1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University[*1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, 95 Yongan Road, Xi-Cheng District, Beijing 100050, China
推荐引用方式(GB/T 7714):
Meng Fandong,Li Wenyan,Zhi Fachao,et al.Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study[J].DIGESTIVE ENDOSCOPY.2021,33(7):1110-1119.doi:10.1111/den.13941.
APA:
Meng Fandong,Li Wenyan,Zhi Fachao,Li Zhaoshen,Xue Zhanxiong...&Zhang Shutian.(2021).Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study.DIGESTIVE ENDOSCOPY,33,(7)
MLA:
Meng Fandong,et al."Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study".DIGESTIVE ENDOSCOPY 33..7(2021):1110-1119